OptiNose, Inc. (NASDAQ:OPTN) COO Sells $84,003.65 in Stock

OptiNose, Inc. (NASDAQ:OPTNGet Rating) COO Ramy A. Mahmoud sold 23,663 shares of the company’s stock in a transaction that occurred on Friday, September 16th. The shares were sold at an average price of $3.55, for a total value of $84,003.65. Following the completion of the transaction, the chief operating officer now directly owns 198,407 shares of the company’s stock, valued at $704,344.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

OptiNose Price Performance

Shares of NASDAQ OPTN opened at $3.67 on Friday. The stock has a fifty day simple moving average of $3.66 and a two-hundred day simple moving average of $2.96. OptiNose, Inc. has a 1-year low of $1.46 and a 1-year high of $4.30.

OptiNose (NASDAQ:OPTNGet Rating) last announced its quarterly earnings data on Thursday, August 11th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). The business had revenue of $20.58 million during the quarter, compared to analyst estimates of $22.30 million. Equities research analysts expect that OptiNose, Inc. will post -0.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On OptiNose

Several institutional investors and hedge funds have recently bought and sold shares of OPTN. Stonepine Capital Management LLC bought a new position in OptiNose during the fourth quarter valued at $6,228,000. Velan Capital Investment Management LP purchased a new stake in shares of OptiNose during the first quarter worth $4,940,000. Opaleye Management Inc. purchased a new stake in shares of OptiNose during the second quarter worth $333,000. Assenagon Asset Management S.A. purchased a new stake in shares of OptiNose during the first quarter worth $212,000. Finally, State Street Corp lifted its position in shares of OptiNose by 87.8% during the first quarter. State Street Corp now owns 176,553 shares of the company’s stock worth $436,000 after acquiring an additional 82,558 shares in the last quarter. 44.67% of the stock is owned by institutional investors.

OptiNose Company Profile

(Get Rating)

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.

Further Reading

Insider Buying and Selling by Quarter for OptiNose (NASDAQ:OPTN)

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.